Guardant Health (GH) said Tuesday that the Centers for Medicare and Medicaid Services has granted Advanced Diagnostic Laboratory Test, or ADLT, status for Guardant's Shield blood test to screen for colorectal cancer.
Guardant said the ADLT designation means the Shield test meets the criteria for providing clinical information that can't be obtained by any other method. The test was approved by the US Food and Drug Administration in 2024 for average-risk individuals 45 years old and older.
The company said the test will be reimbursed at $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。